Oxidative stress in neurodegeneration: cause or consequence?
暂无分享,去创建一个
[1] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.
[2] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[3] G. Wilkin,et al. Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2 , 2000, Molecular and Cellular Neuroscience.
[4] C. Rossi,et al. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression , 2003, Molecular and Cellular Neuroscience.
[5] S. Lorenzl,et al. Minocycline enhances MPTP toxicity to dopaminergic neurons , 2003, Journal of neuroscience research.
[6] M. Miller,et al. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[7] D. Bredesen,et al. Altered Reactivity of Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis , 1996, Science.
[8] E. Stadtman,et al. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[9] A. Manning-Boğ,et al. α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration , 2003, The Journal of Neuroscience.
[10] A. Chakrabartty,et al. Monomeric Cu,Zn-superoxide Dismutase Is a Common Misfolding Intermediate in the Oxidation Models of Sporadic and Familial Amyotrophic Lateral Sclerosis*[boxs] , 2004, Journal of Biological Chemistry.
[11] A. Favier,et al. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[12] Orla Hardiman,et al. “True” sporadic ALS associated with a novel SOD‐1 mutation , 2002, Annals of neurology.
[13] John Hardy,et al. The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.
[14] Joseph S. Beckman,et al. Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.
[15] Syed F. Ali,et al. Methamphetamine‐ and 1‐methyl‐4‐phenyl‐ 1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurotoxicity in inducible nitric oxide synthase‐deficient mice , 1999, Synapse.
[16] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[17] C. Marsden,et al. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease , 2005, Journal of Neural Transmission.
[18] R. Swerdlow,et al. Alzheimer's disease cybrids replicate β‐amyloid abnormalities through cell death pathways , 2000 .
[19] H. Horvitz,et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosis , 1997, Annals of neurology.
[20] Jeffrey Rothstein,et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone–mediated copper loading , 2002, Nature Neuroscience.
[21] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[22] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[23] D. German,et al. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons , 2000, Neuroscience.
[24] N. Robakis,et al. Immunohistochemical evidence of antioxidant stress in Alzheimer's disease , 1992 .
[25] A. Mackinnon,et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.
[26] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[27] J. Uney,et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[28] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[29] G. Uhl,et al. Murine vesicular monoamine transporter 2: molecular cloning and genomic structure. , 1997, Brain research. Molecular brain research.
[30] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[31] J. Andersen,et al. Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson's disease? , 2002, Journal of neurochemistry.
[32] M. Gurney,et al. Relationship of oxygen radical‐induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS , 1998, Journal of neuroscience research.
[33] H. Paulson,et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.
[34] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[35] P Riederer,et al. Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.
[36] J S Beckman,et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. , 1999, Science.
[37] P. Sonsalla,et al. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. , 2000, The Journal of pharmacology and experimental therapeutics.
[38] M. Carrì,et al. Mitochondrial dysfunction due to mutant copper/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine , 2003, Neurobiology of Disease.
[39] K. Jellinger,et al. Iron and ferritin in substantia nigra in Parkinson's disease. , 1993, Advances in neurology.
[40] S. Paul,et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] C. Epstein,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[42] M. Mattson,et al. ALS-Linked Cu/Zn–SOD Mutation Increases Vulnerability of Motor Neurons to Excitotoxicity by a Mechanism Involving Increased Oxidative Stress and Perturbed Calcium Homeostasis , 1999, Experimental Neurology.
[43] M. Asanuma,et al. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. , 2003, Biochimica et biophysica acta.
[44] E. Masliah,et al. α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .
[45] Moonhee Lee,et al. Effect of overexpression of wild‐type and mutant Cu/Zn‐superoxide dismutases on oxidative stress and cell death induced by hydrogen peroxide, 4‐hydroxynonenal or serum deprivation: potentiation of injury by ALS‐related mutant superoxide dismutases and protection by Bcl‐2 , 2001, Journal of neurochemistry.
[46] R. Scott,et al. MPTP Activates c‐Jun NH2‐Terminal Kinase (JNK) and Its Upstream Regulatory Kinase MKK4 in Nigrostriatal Neurons In Vivo , 2000, Journal of neurochemistry.
[47] F. Zemlan,et al. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation , 1989, Brain Research.
[48] J. Connor,et al. Iron acquisition and expression of iron regulatory proteins in the developing brain: manipulation by ethanol exposure, iron deprivation and cellular dysfunction. , 1994, Developmental neuroscience.
[49] H. Aanstoot. Laboratory Standards in the Assessment of the Quality of Care , 1998, Hormone Research in Paediatrics.
[50] C. Masters,et al. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.
[51] M. Gurney,et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.
[52] M. Mattson,et al. Protein modification by the lipid peroxidation product 4‐hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients , 1998, Annals of neurology.
[53] J. Dichgans,et al. Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.
[54] J. Rothstein,et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS , 2002, Annals of neurology.
[55] W. Markesbery,et al. Decrease in Peptide Methionine Sulfoxide Reductase in Alzheimer's Disease Brain , 1999, Journal of neurochemistry.
[56] M. Gurney,et al. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis , 1998, Neurology.
[57] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[58] Shotai Kobayashi,et al. Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite‐mediated oxidative stress in neurodegenerative diseases , 2000, Annals of neurology.
[59] N. Hattori,et al. Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome* , 2002, The Journal of Biological Chemistry.
[60] Wendy Bruening,et al. Up‐Regulation of Protein Chaperones Preserves Viability of Cells Expressing Toxic Cu/Zn‐Superoxide Dismutase Mutants Associated with Amyotrophic Lateral Sclerosis , 1999, Journal of neurochemistry.
[61] C. Haass,et al. Neurotoxic Mechanisms Caused by the Alzheimer's Disease-linked Swedish Amyloid Precursor Protein Mutation , 2003, Journal of Biological Chemistry.
[62] J. Trojanowski,et al. A panel of epitope‐specific antibodies detects protein domains distributed throughout human α‐synuclein in lewy bodies of Parkinson's disease , 2000, Journal of neuroscience research.
[63] Robert H. Brown,et al. Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis , 1997, Annals of neurology.
[64] Hiroshi Nishimune,et al. Motoneuron Death Triggered by a Specific Pathway Downstream of Fas Potentiation by ALS-Linked SOD1 Mutations , 2002, Neuron.
[65] Geoffrey Burnstock,et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice , 2004, Nature Medicine.
[66] Moonhee Lee,et al. Effect of overexpression of wild‐type and mutant Cu/Zn‐superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis , 2001, Journal of neurochemistry.
[67] O. Andreassen,et al. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity , 2000, Neuroreport.
[68] M. Gurney,et al. The Copper Chelator d‐Penicillamine Delays Onset of Disease and Extends Survival in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1997, The European journal of neuroscience.
[69] Ming-tao Li,et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease , 2004, Neuroscience Research.
[70] D. Perl,et al. Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.
[71] Takeshi Hayashi,et al. Oxidative damage to mitochondrial DNA in spinal motoneurons of transgenic ALS mice. , 2001, Brain research. Molecular brain research.
[72] Subramanian Rajagopalan,et al. Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.
[73] J. Bolaños,et al. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage , 1996, Brain Research.
[74] W. Markesbery,et al. Electrochemical Analysis of Protein Nitrotyrosine and Dityrosine in the Alzheimer Brain Indicates Region-Specific Accumulation , 1998, The Journal of Neuroscience.
[75] Betty Y. S. Kim,et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.
[76] M. Cudkowicz,et al. Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity , 2002, Neurology.
[77] S. Canals,et al. Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease , 2001, Journal of neurochemistry.
[78] A. Favier,et al. A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis , 2001 .
[79] G. Sobue,et al. Differential expression of inflammation‐ and apoptosis‐related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis , 2002, Journal of neurochemistry.
[80] T. Morgan,et al. Peroxynitrite Mediates Neurotoxicity of Amyloid β-Peptide1–42- and Lipopolysaccharide-Activated Microglia , 2002, The Journal of Neuroscience.
[81] O. Andreassen,et al. Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine , 2000, The Journal of Neuroscience.
[82] K. Vrana,et al. Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by l-BSO and apoptosis , 2000, Brain Research.
[83] C. Behl,et al. Hydrogen peroxide mediates amyloid β protein toxicity , 1994, Cell.
[84] A. Levey,et al. Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice , 1998, Journal of neurochemistry.
[85] J. Trojanowski,et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.
[86] M. Beal,et al. Manganese Superoxide Dismutase Overexpression Attenuates MPTP Toxicity , 1998, Neurobiology of Disease.
[87] D. Gozal,et al. Increased mitochondrial antioxidative activity or decreased oxygen free radical propagation prevent mutant SOD1‐mediated motor neuron cell death and increase amyotrophic lateral sclerosis‐like transgenic mouse survival , 2002, Journal of neurochemistry.
[88] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[89] T. Montine,et al. Enhanced N‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Toxicity in Mice Deficient in CuZn‐Superoxide Dismutase or Glutathione Peroxidase , 2000, Journal of neuropathology and experimental neurology.
[90] B. Friguet,et al. Inhibition of the multicatalytic proteinase (proteasome) by 4‐hydroxy‐2‐nonenal cross‐linked protein , 1997, FEBS letters.
[91] G. Sobue,et al. Hsp70 and Hsp40 improve neurite outgrowth and suppress intracytoplasmic aggregate formation in cultured neuronal cells expressing mutant SOD1 , 2002, Brain Research.
[92] Voon Wee Yong,et al. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.
[93] L. Ellerby,et al. Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[94] J. Bennett,et al. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[95] M. Gurney,et al. Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis , 1996, Annals of neurology.
[96] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[97] A. Lees,et al. Conjugates of Catecholamines with Cysteine and GSH in Parkinson's Disease: Possible Mechanisms of Formation Involving Reactive Oxygen Species , 1998, Journal of neurochemistry.
[98] D. Godin,et al. Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.
[99] D. Dexter,et al. Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism. , 1995, Biochemical pharmacology.
[100] J. Trojanowski,et al. Nitration of tau protein is linked to neurodegeneration in tauopathies. , 2003, The American journal of pathology.
[101] K. Winklhofer,et al. Inactivation of Parkin by Oxidative Stress and C-terminal Truncations , 2003, Journal of Biological Chemistry.
[102] M. D. Dal Canto. Comparison of pathological alterations in ALS and a murine transgenic model: pathogenetic implications. , 1995, Clinical neuroscience.
[103] M. Beal,et al. Mutated Human SOD1 Causes Dysfunction of Oxidative Phosphorylation in Mitochondria of Transgenic Mice* , 2002, The Journal of Biological Chemistry.
[104] Patrik Brundin,et al. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. , 2002, Human molecular genetics.
[105] D. Mc. Comparison of pathological alterations in ALS and a murine transgenic model: pathogenetic implications. , 1995 .
[106] D. Butterfield,et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death , 2002, Neurobiology of Aging.
[107] H. Forman,et al. Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity , 2000, The Journal of Biological Chemistry.
[108] S. Berman,et al. Dopamine Oxidation Alters Mitochondrial Respiration and Induces Permeability Transition in Brain Mitochondria , 1999, Journal of neurochemistry.
[109] K. McNaught,et al. Altered Glial Function Causes Neuronal Death and Increases Neuronal Susceptibility to 1‐Methyl‐4‐Phenylpyridinium‐ and 6‐Hydroxydopamine‐Induced Toxicity in Astrocytic/Ventral Mesencephalic Co‐Cultures , 1999, Journal of neurochemistry.
[110] Ole A. Andreassen,et al. Mice with a Partial Deficiency of Manganese Superoxide Dismutase Show Increased Vulnerability to the Mitochondrial Toxins Malonate, 3-Nitropropionic Acid, and MPTP , 2001, Experimental Neurology.